Filament Health

Just two weeks ago, Filament Health (OTCQB: FLHLF) was issued a patent by the U. S. Patent and Trademark Office to extract and standardize natural psilocybin. Now, the company announced it was issued a fourth patent by the Canadian Intellectual Property Office. The latest patent describes the...

Filament Health (OTCQB: FLHLF) (NEO:FH) is a clinical-stage psychedelic drug development company creating safe, standardized, naturally-derived psychedelic medicines.  CEO and Co-Founder Benjamin Lightburn spoke at the Benzinga Psychedelics Capital Conference, April 19, 2022, about the...

Filament Health Corp. (OTCQB: FLHLF) announced that the U. S. Patent and Trademark Office (USPTO) issued a patent that will allow the company to extract and standardize natural psilocybin and associated psychedelic compounds. Benjamin Lightburn, CEO of the company, commented: “The...

Image by Mathew Schwartz from Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Psilocybin, the commonly-known primary compound in magic mushrooms, is widely believed to be a...